全部

1·This article reviews the pathology and prevention for in-stent restenosis.

现就支架再狭窄的病理及其防治作一综述。

2·In-stent restenosis has been significantly reduced by utilization of drug eluting stents.

药物涂层支架的应用显著降低了支架内再狭窄的发生。

3·In-stent restenosis is the major factor influencing the results of percutaneous coronary intervention.

支架内再狭窄是影响经皮冠状动脉介入治疗疗效的主要原因。

4·Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis.

涂渍紫杉醇的球囊导管与涂渍紫杉醇的支架在治疗支架内在狭窄中的比较。

5·The in-stent restenosis is one of the main complications in coronary artherosclerotic heart disease patients after PTCA and PCI.

术后靶血管管腔再狭窄是冠状动脉介入治疗术的主要并发症，如何有效预防再狭窄已成为目前介入心脏医学界的主要课题之一。

6·Objective To assess the safety and therapeutical efficiency of dual-wire balloon using in treating coronary artery in-stent restenosis.

目的评价双导丝球囊在冠脉支架内再狭窄治疗中的的安全性和疗效。

7·Objective To evaluate the safety and efficacy of cutting balloon angioplasty (CBA) for diffuse in-stent restenosis (ISR) in elderly patients.

目的研究切割球囊成形术（CBA）治疗高龄患者弥漫性冠状动脉（冠脉）支架内再狭窄（ISR）的安全性与疗效。

8·Objective To explore the experience about off-pump coronary artery bypass grafting (OPCAB) for the treatment of in-stent restenosis in coronary disease.

目的探讨非体外循环冠状动脉旁路移植术(OPCAB)对老年冠心病患者冠状动脉支架再狭窄的治疗经验。

9·Objective to assess the accuracy and the clinical value of dual-source computed tomography (DSCT) for detecting in-stent restenosis of the coronary arteries.

目的评估双源ct在冠状动脉支架置入术后再狭窄诊断的准确度，评价其在支架置入术后复查中的临床随访价值。

10·The use of SES implantation was not restricted to on-label indications, and target lesions included in-stent restenosis, vein graft, left main stem locations, bifurcations, and long lesions.

SES置入不受“标签”适应证的限制，靶病变包括支架内再狭窄、静脉搭桥、左主干局部病变、分叉病变和长病变。